We apply our skills and experience to develop, adapt, and optimize dedicated assays for your discovery programs. We know that the biology of the drug target needs to be addressed in a pharmacologically-relevant manner, that optimized HTS and hit profiling assays need to be robust, and that economic factors need to be considered. Sometimes these requirements conflict; we will use our expertise to balance these factors while enabling successful screening or hit profiling campaigns.
We have an in-depth understanding of assay requirements for many target classes and assay formats, including:
- Kinases, phosphatases, proteases
- Epigenetics targets (HDAC, HMT, HDM, DUB)
- Other enzyme families
- Protein-protein interaction
Cell based assays
- GPCR and non-GPCR receptors
- Ion channels
- Phenotypic changes
- Whole cell binding
Our assay development capabilities cover various types of enzyme activity, biochemical interaction or displacement assays; cell-based second messenger, metabolite, receptor or transporter assays; phenotypic changes, and microbial viability and reporter gene assays.
Relevant counter, orthogonal or selectivity assays are co-developed for characterization of hits identified in the primary high throughput screening campaign.
Our expertise and your input are the keys to success.